reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Emanuel Gil-Av (Zimkin) (Hebrew: עמנואל גיל-אב; 7 August 1916 – 24 March 1996) was an Israeli chemist. The main emphasis of his work constituted chiral chromatography for the analytical separation of enantiomers.
=== Transcriptional variants === So far, three different transcription variants (TVs) have been described for CK1δ in humans (Homo sapiens), mice (Mus musculus), and rats (Rattus norvegicus), which are highly homologous. The alignment of all CK1δ sequences of all organisms shows a high homology in the first 399 amino acids, except for position 381. While the human transcription variants are using isoleucine, the mouse and rat sequences incorporate a valine instead. The only exception is rat TV3, which is also transcribing its nucleotide sequence into an isoleucine. After position 399, three different general structures can be observed. The first variant consists of 415 amino acids across all three organisms and is called TV1 in human and rat, while the murine counterpart is named CRAa. The shortest group of sequences consists of 409 amino acids: TV2 in humans and rats, CRAc in mice. The longest variant consists of 428 amino acids in rat (TV3) and mice (CRAb), while the human (TV3) variant is missing the second to last amino acid (threonine), resulting in a protein of a length of 427 amino acids. The various transcription variants are based on a different usage of the exons that are encoding for CSNK1D. The whole gene consists of eleven different exons and is located in humans on chromosome 17 at position 17q25.3. CSNK1D has a length of 35kb and is overlapping with the gene Slc16a3. The intersecting part is exon 11, which is located downstream of exon 10. However, it does not interfere with Slc16a3 since it is located in a non-coding area.
=== Filming === Scouting began in the beginning of July. The table read for the first episode was announced to occur on July 14, 2015, by Kerry Washington. The title of the season premiere, "Heavy is the Head" was revealed on August 8, 2015, by its director Tom Verica on Twitter. Filming for the season began on July 16, 2015. Several actors working on ShondaLand-produced shows directed an episode for the fifth season. Tony Goldwyn from Scandal directed the second and 17th episodes, making it the fourth and fifth episodes he has directed on the show. Chandra Wilson, who plays Dr. Miranda Bailey on Grey's Anatomy, directed her first Scandal episode, which was the sixth episode "Get Out of Jail, Free". Scott Foley from Scandal also directed his first Scandal episode, the 16th named "The Miseducation of Susan Ross". Foley's director-debut was announced on Twitter by Foley himself and executive producer Tom Verica.
December 7, 1995: Decree concerning the responsibilities of the Minister Delegate for Employment. June 6, 1996: Manifesto for gender parity published in L'Express; ten women, including former prominent ministers, are its authors. July 5, 1996: Law concerning adoption. January 14, 1997: Publication of selected excerpts from lawyer Gisèle Halimi's report to the Prime Minister on gender inequalities (social, economic, political), which undermine aspects of democracy; the report also proposes various solutions to reduce these inequalities and promote better democracy. June 11, 1997: Decree concerning the responsibilities of the Minister of Employment and Solidarity. December 19, 1997: Social Security Financing Law for 1998; it includes provisions relating to the family. March 8, 1998: Circular concerning the feminization of job titles, functions, ranks, or titles. March 16, 1998: Law concerning nationality. May 11, 1998: Law concerning the entry and residence of foreigners in France and the right of asylum. June 17, 1998: Constitutional bill for gender equality, including possibilities for measures promoting gender parity in political positions. June 17, 1998: Law concerning the prevention and repression of sexual offenses and the protection of minors. November 17, 1998: A State Secretariat for Women's Rights and Vocational Training is delegated to the Ministry of Employment and Solidarity. December 23, 1998: Social Security Financing Law for 1999, notably modifying certain elements relating to family allowances and the back-to-school allowance.
Sources: en.wikipedia.org
According to Rhie, the "Cave of the Musicians" is probably the earliest of the "central pillar" caves at Kizil, dated to the mid-4th century CE, and its iconography is also among the earliest. Carbon testing by Su Bai gave dates ranging from 310 +/-80 CE to 350 +/-60 CE (i.e. a maximum range of 230-410 CE). Huo and Wang attributed the cave to the Second Period, giving it a date from mid-4th to late 5th century (circa 350–499 CE). The traditional German datation estimated the cave to be from the 600–650 CE period, and presented it as an example of the later "Blue-green style", said to succeed chronologically the "Orange-green style" group. The so-called "central pillar" which appears on a plan is actually not a pillar at all but only the rock at the back of the cave, into which was bored a circular corridor allowing for circumambulation. There is a niche in the "central pillar" designed to house a statue of the Buddha, and two other niches on each side of the main entrance, and niches in the back corridor. The central niche probably depicted the Buddha meditating in the Indrasala Cave, with a background decoration of a mountain, a recurring central theme at Kizil. Maitreya, the Buddha of the future, in the Tusita Heaven, appears in a beautiful mural over the exit door. Structurally, the cave remains relatively simple, as it does not have an anteroom or vestibule. The style of the paintings is derived from the Art of Gandhara and Kashmir, the Art of Mathura and early Gupta art, with striking influences from Roman art and the art of Palmyra.
The AToFMS allows for the determination of mixing state, or distribution of chemical species, within individual particles. These mixing states are important in the determination of climate and health impact of aerosols. The schematic of a typical AToFMS is shown to the right. The overall structure of ATOF instruments is; sampling, sizing, and the mass analyzer region. The inlet system is similar to the AMS by using the same aerodynamic focusing lens, but it has smaller orifices because of its analysis of single particles. In the sizing region particle passes through the first continuous solid state laser that generates an initial pulse of scattered light. Then the particle passes through the second laser that is orthogonal to the first and produces a pulse of scattered light. The light is detected by a photomultiplier (PMT) that is matched up to each laser. Using the transit times between the two detected pulses and the fixed distance the velocity and size of each particle is calculated. Next the particles travel through to the mass analyzer region where it is ionized by a pulsed LDI laser, which is timed to hit the particle as it reaches the center of the ion extraction region. Once ionized, the positive ions are accelerated towards the positive ToF section and the negative ions are accelerated towards the negative ToF section where they are detected.
== Military applications == Depleted uranium is very dense; at 19,050 kg/m3, it is 1.67 times as dense as lead, only slightly less dense than tungsten and gold, and only 16% less than osmium or iridium, which are the densest known substances under standard (i.e., Earth-surface) pressures. Consequently, a DU projectile of given mass has a smaller diameter than an equivalent lead projectile with the same kinetic energy, with less aerodynamic drag and deeper penetration because of a higher pressure at point of impact. DU projectiles are inherently incendiary because they become pyrophoric upon impact with the target.
=== Antimalarial === During WWII a British team led by Frank Rose discovered (see details there) that some biguanides are useful as antimalarial drugs. Much later it was demonstrated that they are prodrugs metabolised into active dihydrotriazine derivatives which, until recently, were believed to work by inhibiting dihydrofolate reductase. Examples include:
=== Abkhazia === When Abkhazia launched a military operation to gain the Kodori Gorge, President Sergei Bagapsh said that the events in South Ossetia "accelerated the implementation of military measures that had been planned earlier." Bagapsh also said: "Maybe in order to achieve our goals we will have to violate certain parts of the Moscow Agreement of May 14, 1994 on a ceasefire but we were not the first to violate them."
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.